1.	Phase II Randomized Study of SCH 66336 vs Gemcitabine in Patients with Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 01/2000) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CWRU-SCH-1298, SPRI-C98-545-18, NCI-G99-1534
2.	Phase II Randomized Study of SCH 66336 Versus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 01/2000) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-98115, SPRI-C98-545-12, NCI-G99-1571
3.	Phase II Study of SCH 66336 in Patients With Metastatic Adenocarcinoma of the Pancreas Refractory to Gemcitabine (Summary Last Modified 03/2000) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-9906030, SPRI-P00346, NCI-G99-1610
4.	SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: EORTC-16997, EORTC-GU-16997, EORTC-PAMM-16997, NCT00006351
5.	Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)(COMPLETED) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P02530, NCT00073450
6.	Phase II Randomized Study of Anastrozole With or Without Lonafarnib in Postmenopausal Women With Hormone Receptor-Positive Stage IIIB, IIIC or IV Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: Postmenopausal Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0403073-01, SPRI-P03480, NCT00098904
7.	Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: AGO-OVAR 15, NCT00281515
8.	Phase I Study of SCH 66336 with Fluorouracil and Leucovorin Calcium in Patients with Advanced Cancer (Summary Last Modified 04/2000). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-99020, SPRI-C98-564-01, NCI-G99-1540, NCT00003956
9.	Phase I Study of Oral SCH 66336 in Patients with Solid Tumors (Summary Last Modified 04/2000) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EORTC-16979, SPRI-I97-211
10.	Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: EORTC-16023-10051, SPRI-P01900, NCT00068757
11.	Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia Phase: Phase I Type: Treatment Status: Completed Age: 16 and over Sponsor: Other Protocol IDs: ID02-221, NCT00047502
12.	Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED) Phase: Phase I Type: Treatment Status: Completed Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: P01964, NCT00040547
13.	Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: CDR0000362066, EORTC-16027, EORTC-26023, SPRI-P03174, NCT00083096
14.	Sarasar and Temodar for Glioblastoma Multiforme Patients Phase: Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: 2004-0424, SPRI # P04084, NCT00102648
15.	PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: Pro00005027, 7009/Pro00005027, NCT00612651
16.	SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors Phase: Phase I Type: Treatment Status: Completed Age: 21 and under Sponsor: NCI, Other Protocol IDs: CDR0000068571, PBTC-003, SPRI-P02201, NCT00015899